drugset / Trial / NCT05737771

To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

NCT05737771

Phase 1 Unknown 40 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

To compare the safety and pharmacokinetic properties between the administration of DWP16001 and DWC202213 as an individual drug, and the administration of DWJ1563 as a combination drug.

Timeline

Start
2023-01-25
Primary completion
2023-03-31
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject DWC202213 Unknown
Subject DWJ1563 Unknown
Subject Enavogliflozin Small molecule